In a recent symposium hosted by the Association for American Cancer Institutes’ Cancer Research Innovation, Yunu, a provider of medical research technology and services, brought to light significant concerns regarding imaging assessments in clinical trials.
Panelists presented findings from a newly released abstract indicating that half of all imaging assessments in ongoing trials exhibited non-conformities. The session was further enriched by insights from two other panelists whose sites have implemented Yunu’s trial imaging platform, confirming these findings.
The three abstracts discussed were based on similar methodologies and revealed error rates of 25%, 30%, and 50% within oncology clinical trial imaging endpoints. Remarkably, these error rates were successfully reduced to less than two percent using Yunu’s platform. The discussion highlighted the widespread impact of imaging issues, including delayed trial activation, incorrect patient enrollments, increased costs, audit findings, and data loss. A recent study also underscored that the financial burden of imaging on ineligible patients exceeded the entire imaging costs of the trial.
Yunu’s platform has emerged as a pivotal tool in enhancing imaging accuracy and efficiency in clinical trials. It ensures compliance in trial imaging, delivering up to 80% workflow efficiencies for study staff, a 50% acceleration in reading team performance, seamless cross-site resource sharing, audit-ready imaging data management, comprehensive reporting at both trial and patient levels, reader training and scheduling, and customizable dashboards for overseeing all trials and sites.
Jeff Sorenson, Yunu co-founder and CEO, emphasized the growing adoption of Yunu’s platform among research site networks, national cancer centers, and community oncology practice groups. He noted that many of these sites cover wide geographic areas. “The current model of in-house radiology research cores using non-specialized tools and manual, error-prone processes is no longer sustainable. The data presented by the panelists show that imaging assessments cannot be effectively managed even in leading cancer centers under this model, making it unrealistic to expect success in community oncology settings, where 80% of Americans receive care,” Sorenson stated.